Related Experiment Video

Updated: Mar 29, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Oligoprogression in NSCLC with Other Actionable Oncogenic Drivers Beyond EGFR and ALK: An Emerging Entity

Ilaria Mariangela Scaglione1, Adele Bonato1, Alessandra Dodi2,3

  • 1Section of Innovation Biomedicine-Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona School of Medicine and Verona University Hospital Trust, 37134 Verona, Italy.

International Journal of Molecular Sciences
|March 28, 2026
PubMed

Insights

Oligoprogressive disease (OPD) in non-small-cell lung cancer (NSCLC) patients may benefit from local ablative treatment (LAT). Evidence for LAT in NSCLC with drivers other than EGFR/ALK is limited, highlighting a need for more research.

Area of Science:

  • Oncology
  • Medical Oncology
  • Lung Cancer Research

Background:

  • Oligoprogressive disease (OPD) presents unique challenges in non-small-cell lung cancer (NSCLC) management.
  • Local ablative treatment (LAT) shows survival benefits for OPD patients during systemic therapy.
  • The role of LAT in OPD is well-studied for EGFR-mutant and ALK-rearranged NSCLC but underexplored for other oncogenic drivers.

Purpose of the Study:

  • To review current data on standard treatments for NSCLC with OPD and drivers other than EGFR/ALK.
  • To specifically assess the role and evidence for LAT in this patient population during systemic treatment.
  • To identify gaps in knowledge and future research directions.

Main Methods:

  • Comprehensive literature search of PubMed and ClinicalTrials.gov.
  • Inclusion of data from case reports, retrospective series, and ongoing clinical trials.
  • Focus on NSCLC with actionable oncogenic drivers excluding EGFR and ALK.

Main Results:

  • Limited evidence currently supports the use of LAT in OPD for NSCLC with drivers other than EGFR/ALK.
  • Existing data primarily consists of case reports and small retrospective studies.
  • Several clinical trials are ongoing, indicating active research in this area.

Conclusions:

  • There is a significant unmet clinical need for robust evidence regarding LAT in OPD for NSCLC with non-EGFR/ALK drivers.
  • Systematic and multicentric data collection is crucial to generate stronger evidence.
  • Further research is warranted to optimize treatment strategies for these patients.
Keywords:
less common actionable oncogenic driverslocal ablative treatmentnon-small cell lung canceroligoprogressive diseasetargeted therapy

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

514

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
Tumor Progression02:07

Tumor Progression

3.5K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.9K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

6.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K